ID   NB4-S1
AC   CVCL_U086
DR   cancercelllines; CVCL_U086
DR   TOKU-E; 4157
DR   Wikidata; Q54907534
RX   PubMed=9342843;
RX   PubMed=9716606;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:15367; All-trans-retinoic acid (ATRA; Tretinoin).
CC   Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala18Asp (c.53C>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C3182; Acute promyelocytic leukemia with PML-RARA
DI   ORDO; Orphanet_520; Acute promyelocytic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0005 ! NB4
SX   Female
AG   23Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 05-10-23; Version: 19
//
RX   PubMed=9342843; DOI=10.1046/j.1432-0436.1997.6150321.x;
RA   Nason-Burchenal K., Maerz W., Albanell J., Allopenna J., Martin P.,
RA   Moore M.A.S., Dmitrovsky E.;
RT   "Common defects of different retinoic acid resistant promyelocytic
RT   leukemia cells are persistent telomerase activity and nuclear body
RT   disorganization.";
RL   Differentiation 61:321-331(1997).
//
RX   PubMed=9716606; DOI=10.1182/blood.V92.5.1758;
RA   Nason-Burchenal K., Allopenna J., Begue A., Stehelin D.,
RA   Dmitrovsky E., Martin P.;
RT   "Targeting of PML/RARalpha is lethal to retinoic acid-resistant
RT   promyelocytic leukemia cells.";
RL   Blood 92:1758-1767(1998).
//